Статья

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma

Martin HutchingsFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkAnnika LoftFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkMads HansenFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkLars Møller PedersenFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkThora BuhlFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkJesper JurlanderPET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkSimon BuusFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkSusanne KeidingFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkFrancesco d’AmoreFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkA. M. BoesenFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkAnne Kiil BerthelsenFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, DenmarkLena SpechtFrom the Department of Clinical Physiology and Nuclear Medicine, Positron Emission Tomography (PET) and Cyclotron Unit, and the Departments of Haematology, Radiotherapy, and Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; the Department of Haematology, University Hospital Herlev, Copenhagen, Denmark; and the PET Center and the Department of Haematology, Aarhus University Hospital, Aarhus, Denmark

2005en

ABI

Аннотация

Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis. This investigation prospectively assessed the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS) in Hodgkin lymphoma (HL). Seventy-seven consecutive, newly diagnosed patients underwent FDG-PET at staging, after two and four cycles of chemotherapy, and after completion of chemotherapy. Median follow-up was 23 months. After two cycles of chemotherapy, 61 patients had negative FDG-PET scans and 16 patients had positive scans. Eleven of 16 FDG-PET-positive patients progressed and 2 died. Three of 61 FDG-PET-negative patients progressed; all were alive at latest follow-up. Survival analyses showed strong associations between early FDG-PET after two cycles and PFS (P < .001) and OS (P < .01). For prediction of PFS, interim FDG-PET was as accurate after two cycles as later during treatment and superior to computerized tomography (CT) at all times. In regression analyses, early interim FDG-PET was stronger than established prognostic factors. Other significant prognostic factors were stage and extranodal disease. Early interim FDG-PET is a strong and independent predictor of PFS in HL. A positive early interim FDG-PET is highly predictive of progression in patients with advanced-stage or extranodal disease.

Перевод пока недоступен

Идентификаторы

DOI: 10.1182/blood-2005-06-2252

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar